Skip to main content
. 2016 Jul 5;34(25):2997–3004. doi: 10.1200/JCO.2015.65.4582

Fig 1.

Fig 1.

(A) Progression-free (PFS) and (B) overall survival (OS) of patients receiving CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for eight cycles (CHOP8) or CHOP for three cycles plus radiotherapy (CHOP3RT) with prolonged follow-up. 5-, 10-, and 15-year estimates are included. (*) Two-sided log-rank test.